These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 27124905)

  • 1. Identification of Factors Affecting the Success of Next-Generation Sequencing Testing in Solid Tumors.
    Goswami RS; Luthra R; Singh RR; Patel KP; Routbort MJ; Aldape KD; Yao H; Dang HD; Barkoh BA; Manekia J; Medeiros LJ; Roy-Chowdhuri S; Stewart J; Broaddus RR; Chen H
    Am J Clin Pathol; 2016 Feb; 145(2):222-37. PubMed ID: 27124905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factors affecting the success of next-generation sequencing in cytology specimens.
    Roy-Chowdhuri S; Goswami RS; Chen H; Patel KP; Routbort MJ; Singh RR; Broaddus RR; Barkoh BA; Manekia J; Yao H; Medeiros LJ; Staerkel G; Luthra R; Stewart J
    Cancer Cytopathol; 2015 Nov; 123(11):659-68. PubMed ID: 26230354
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of cytocentrifugation supernatant fluid and formalin-fixed paraffin-embedded tissue for targeted next-generation sequencing.
    Janaki N; Harbhajanka A; Michael CW; Bomeisl P; Wasman J; Atchley M; Miskiewicz K; Alouani D; Sadri N
    Cancer Cytopathol; 2019 May; 127(5):297-305. PubMed ID: 30933438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors Impacting Clinically Relevant RNA Fusion Assays Using Next-Generation Sequencing.
    Ramani NS; Patel KP; Routbort MJ; Alvarez H; Broaddus R; Chen H; Rashid A; Lazar A; Lucas FAS; Yao H; Manekia J; Dang H; Barkoh BA; Medeiros LJ; Luthra R; Roy-Chowdhuri S
    Arch Pathol Lab Med; 2021 Nov; 145(11):1405-1412. PubMed ID: 33493304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of an integrated clinical workflow for targeted next-generation sequencing of low-quality tumor DNA using a 51-gene enrichment panel.
    Choudhary A; Mambo E; Sanford T; Boedigheimer M; Twomey B; Califano J; Hadd A; Oliner KS; Beaudenon S; Latham GJ; Adai AT
    BMC Med Genomics; 2014 Nov; 7():62. PubMed ID: 25395014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeted Next Generation Sequencing as a Reliable Diagnostic Assay for the Detection of Somatic Mutations in Tumours Using Minimal DNA Amounts from Formalin Fixed Paraffin Embedded Material.
    de Leng WW; Gadellaa-van Hooijdonk CG; Barendregt-Smouter FA; Koudijs MJ; Nijman I; Hinrichs JW; Cuppen E; van Lieshout S; Loberg RD; de Jonge M; Voest EE; de Weger RA; Steeghs N; Langenberg MH; Sleijfer S; Willems SM; Lolkema MP
    PLoS One; 2016; 11(2):e0149405. PubMed ID: 26919633
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Profiling cancer gene mutations in clinical formalin-fixed, paraffin-embedded colorectal tumor specimens using targeted next-generation sequencing.
    Zhang L; Chen L; Sah S; Latham GJ; Patel R; Song Q; Koeppen H; Tam R; Schleifman E; Mashhedi H; Chalasani S; Fu L; Sumiyoshi T; Raja R; Forrest W; Hampton GM; Lackner MR; Hegde P; Jia S
    Oncologist; 2014 Apr; 19(4):336-43. PubMed ID: 24664487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Versatile ion S5XL sequencer for targeted next generation sequencing of solid tumors in a clinical laboratory.
    Mehrotra M; Duose DY; Singh RR; Barkoh BA; Manekia J; Harmon MA; Patel KP; Routbort MJ; Medeiros LJ; Wistuba II; Luthra R
    PLoS One; 2017; 12(8):e0181968. PubMed ID: 28767674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validation of the Oncomine
    Williams HL; Walsh K; Diamond A; Oniscu A; Deans ZC
    Virchows Arch; 2018 Oct; 473(4):489-503. PubMed ID: 30105577
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Amplicon-Based Targeted Next-Generation Sequencing of Formalin-Fixed, Paraffin-Embedded Tissue.
    Strengman E; Barendrecht-Smouter FAS; de Voijs C; de Vree P; Nijman IJ; de Leng WWJ
    Methods Mol Biol; 2019; 1908():1-17. PubMed ID: 30649717
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Young investigator challenge: Can the Ion AmpliSeq Cancer Hotspot Panel v2 be used for next-generation sequencing of thyroid FNA samples?
    Bellevicine C; Sgariglia R; Malapelle U; Vigliar E; Nacchio M; Ciancia G; Eszlinger M; Paschke R; Troncone G
    Cancer Cytopathol; 2016 Nov; 124(11):776-784. PubMed ID: 27717198
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-clinical validation of a next generation sequencing testing panel.
    Lüsebrink J; Pieper M; Tillmann RL; Brockmann M; Schildgen O; Schildgen V
    Exp Mol Pathol; 2018 Jun; 104(3):170-174. PubMed ID: 29641993
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Utilization of cytology smears improves success rates of RNA-based next-generation sequencing gene fusion assays for clinically relevant predictive biomarkers.
    Ramani NS; Chen H; Broaddus RR; Lazar AJ; Luthra R; Medeiros LJ; Patel KP; Rashid A; Routbort MJ; Stewart J; Tang Z; Bassett R; Manekia J; Barkoh BA; Dang H; Roy-Chowdhuri S
    Cancer Cytopathol; 2021 May; 129(5):374-382. PubMed ID: 33119213
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using "residual" FNA rinse and body fluid specimens for next-generation sequencing: An institutional experience.
    Wei S; Lieberman D; Morrissette JJ; Baloch ZW; Roth DB; McGrath C
    Cancer Cytopathol; 2016 May; 124(5):324-9. PubMed ID: 26682952
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter validation of cancer gene panel-based next-generation sequencing for translational research and molecular diagnostics.
    Hirsch B; Endris V; Lassmann S; Weichert W; Pfarr N; Schirmacher P; Kovaleva V; Werner M; Bonzheim I; Fend F; Sperveslage J; Kaulich K; Zacher A; Reifenberger G; Köhrer K; Stepanow S; Lerke S; Mayr T; Aust DE; Baretton G; Weidner S; Jung A; Kirchner T; Hansmann ML; Burbat L; von der Wall E; Dietel M; Hummel M
    Virchows Arch; 2018 Apr; 472(4):557-565. PubMed ID: 29374318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Targeted High-Throughput Next-Generation Sequencing Panel for Clinical Screening of Mutations, Gene Amplifications, and Fusions in Solid Tumors.
    Luthra R; Patel KP; Routbort MJ; Broaddus RR; Yau J; Simien C; Chen W; Hatfield DZ; Medeiros LJ; Singh RR
    J Mol Diagn; 2017 Mar; 19(2):255-264. PubMed ID: 28017569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salvaging the supernatant: next generation cytopathology for solid tumor mutation profiling.
    Roy-Chowdhuri S; Mehrotra M; Bolivar AM; Kanagal-Shamanna R; Barkoh BA; Hannigan B; Zalles S; Ye W; Duose D; Broaddus R; Staerkel G; Wistuba I; Medeiros LJ; Luthra R
    Mod Pathol; 2018 Jul; 31(7):1036-1045. PubMed ID: 29463880
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of next-generation sequencing and mutation-specific platforms in clinical practice.
    Hinrichs JW; van Blokland WT; Moons MJ; Radersma RD; Radersma-van Loon JH; de Voijs CM; Rappel SB; Koudijs MJ; Besselink NJ; Willems SM; de Weger RA
    Am J Clin Pathol; 2015 Apr; 143(4):573-8. PubMed ID: 25780010
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of Pre-Analytic Factors Affecting the Success of Clinical Next-Generation Sequencing of Solid Organ Malignancies.
    Chen H; Luthra R; Goswami RS; Singh RR; Roy-Chowdhuri S
    Cancers (Basel); 2015 Aug; 7(3):1699-715. PubMed ID: 26343728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality control material for the detection of somatic mutations in fixed clinical specimens by next-generation sequencing.
    Dumur CI; Almenara JA; Powers CN; Ferreira-Gonzalez A
    Diagn Pathol; 2015 Sep; 10():169. PubMed ID: 26376646
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.